Care Access Polska Sp. z o.o.
- Address
- Ul. Zwierzyniecka 6/u4, 00-719 Warsaw, Poland
Care Access Polska Sp. z o.o.
Care Access Polska Sp. z o.o. is a clinical research center specializing in diverse therapeutic areas, with a strong focus on gastroenterology, psychiatry, and cardiovascular disease prevention. The center demonstrates expertise in conducting complex, multi-phase clinical trials evaluating novel therapeutic agents across various disease states, from inflammatory conditions to mental health disorders and cardiovascular risk management.
- Inflammatory bowel diseases, particularly ulcerative colitis (UC) with moderate to severe disease activity
- Major depressive disorder (MDD) with specific focus on treatment-resistant depression and anhedonia
- Cardiovascular disease prevention in high-risk populations with elevated lipoprotein(a)
The research center's portfolio includes innovative studies examining adjunctive therapy approaches for mental health conditions and preventive cardiovascular interventions targeting novel biomarkers. Their involvement in placebo-controlled trials evaluating GS-1427 for ulcerative colitis, aticaprant for depression relapse prevention, and olpasiran for cardiovascular event reduction demonstrates their commitment to advancing treatment options across multiple medical specialties and their capability to manage trials focusing on both disease management and primary prevention strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1AstraZeneca AB4active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Care Access Polska Sp. z o.o.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO). | AstraZeneca AB | Phase II | Recruiting | Sep 2025 | — |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 2 | Unknown | 2025-05-07 | 2025-05-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.